Investors & Partners
Empowering us to help patients with colitis
Investors
AbbVie strategic partnership
The support of AbbVie Ventures, the strategic venture capital arm of AbbVie Inc - world leaders in treatment of inflammatory diseases - has accelerated the development of our gut epithelial shield. The additional advisory support of the AbbVie Inc Immunology team enhances our scientific capabilities, bringing invaluable insight and direction to our innovative approach.
“Despite recent advances, patients with Inflammatory Bowel Disease (IBD) are still suffering. AbbVie Ventures invests in opportunities to deliver future pipeline substrates with the potential to break through the therapeutic ceiling in diseases like IBD. We are excited to partner with ThirtyFiveBio to explore the potential therapeutic benefit of targeting GPR35 for the treatment of IBD.” Timothy Radstake, M.D., Ph.D, Vice President and Global Head of Immunology Discovery Research, AbbVie Inc.
"Our discussions with the teams at AbbVie Ventures, as well as Canaan and Mayewell Capital, generated an appreciation for both our competitive differentiation and scientific thought leadership."
James Westcott, CEO, ThirtyFiveBio.
Advisors and Collaborators
Dr Nicole Kaneider
Principal Investigator at University of Cambridge
Prof Simon Travis
Former President of ECCO,
Professor of Clinical Gastroenterology at The Kennedy Institute, University of Oxford
Prof Laurent Peyrin-Biroulet
IBD Clinical KOL & Former President of ECCO,
Professor of Clinical Gastroenterology at The University of Nancy
Annette Schwartz
Senior Director Abbvie,
Immunology Discovery Research
Prof Graeme Milligan
Prof. of Molecular Pharmacology at The University of Glasgow
Prof Chris Buckley
Professor of Translational Rheumatology and Director of Clinical Research at The Kennedy Institute, University of Oxford
Find out more about our team
Testimonials
See what our investors and partners have to say about ThirtyFiveBio
.png)
"Epithelial repair is neglected in the treatment of colitis, although our research has shown that it is essential (in addition to controlling inflammation) to achieve mucosal healing. ThirtyFiveBio have an exciting novel compound that aims to address this unmet need without increasing immunosuppression."
Prof Simon Travis
Professor of Clinical Gastroenterology at The Kennedy Institute, University of Oxford
"What drew us to ThirtyFiveBio was their rare combination of deep scientific insight and an execution-driven team [...]. They are transforming world-class science into a precision approach for inflammatory bowel disease—one that’s as innovative as it is necessary, and holds real promise to change patients’ lives."
John Zhu, Ph.D.
Founder and President, Mayewell Capital
